Pharmaceutical composition containing polypeptides F1 and F3 and application of pharmaceutical composition in treatment of HPV (Human Papilloma Virus) infected diseases

A composition and drug technology, applied in the field of polypeptide pharmaceutical preparations, can solve the problems of HPV infection that cannot be cured, many side effects, and high recurrence rate, and achieve the effects of unique drug action mechanism, low recurrence rate, and small side effects

Active Publication Date: 2017-05-31
ZHONG AO BIOMEDICAL TECH (GUANGDONG) CO LTD
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] The purpose of the present invention is to overcome the defects of existing treatment methods such as condyloma acuminata or solid tumors that cannot cure HPV-infected related warts, low curative effect, high recurrence rate, many side effects, long course of treatment, high cost, etc., and provide a method comprising F1, The pharmaceutical composition of F3 polypeptide is used for treating diseases related to warts or solid tumors infected by HPV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing polypeptides F1 and F3 and application of pharmaceutical composition in treatment of HPV (Human Papilloma Virus) infected diseases
  • Pharmaceutical composition containing polypeptides F1 and F3 and application of pharmaceutical composition in treatment of HPV (Human Papilloma Virus) infected diseases
  • Pharmaceutical composition containing polypeptides F1 and F3 and application of pharmaceutical composition in treatment of HPV (Human Papilloma Virus) infected diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Embodiment 1: Preparation of F1, F3 polypeptides

[0050] 1) First, a 9-volt direct current stimulation is used to induce the tree frog to secrete a white viscous liquid. The tree frog is distributed in the coastal rainforest area of ​​eastern Australia.

[0051] 2) Collect the liquid and transfer it to ultrapure water containing 20% ​​methanol, shake it and filter it through a 0.45 μm PVDF membrane.

[0052] 3) The filtered supernatant was dried in a vacuum low-temperature centrifugal desiccant to form a white solid powder.

[0053] 4) Dissolve the white solid powder in 0.1% trifluoroacetic acid, and analyze the polypeptide sequence and post-translational modification therein by high-throughput high-performance liquid chromatography and mass spectrometry.

[0054] 5) Use the solid-phase peptide synthesis method to synthesize peptide F1 or F3 respectively. The specific steps are as follows:

[0055] a) On the CS336X peptide synthesizer, using chloromethyl polystyrene ...

Embodiment 2

[0061] Example 2: Preparation of an ointment composition comprising F1 and F3 polypeptides (prepared in 10 g amount)

[0062] formula:

[0063] F1 polypeptide: 10mg;

[0064] F3 polypeptide: 10mg;

[0065] PEG4000: 100 mg;

[0066] Arginine: 20 mg;

[0067] PEG400: Appropriate amount, add up to 10g.

[0068] According to the conventional method for preparing ointment compositions, the above-mentioned composition is divided into aluminum tubes for ointment packaging, and each tube contains 2 mg, 5 mg or 10 mg, which is an ointment.

Embodiment 3

[0069] Example 3: Preparation of an ointment composition comprising F1, F3 polypeptide and Imiquimod (prepared in 10 g amount)

[0070] formula:

[0071] F1 polypeptide: 2.5mg;

[0072] F3 polypeptide: 2.5mg;

[0073] Imiquimod: 30mg

[0074] PEG3000: 100 mg;

[0075] Lysine: 5 mg;

[0076] PEG200: Appropriate amount, add up to 10g.

[0077] According to the conventional method for preparing ointment compositions, the above composition is divided into aluminum tubes for ointment packaging, and each tube contains 2 mg, 5 mg or 10 mg, which is an ointment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of polypeptide pharmaceutical preparations, and in particular relates to a pharmaceutical composition containing polypeptides F1 and F3 and application of the pharmaceutical composition in treatment of HPV infected diseases. The content of the polypeptides F1 and F3 or a mixture of the two polypeptides is 3-30 mu g in every part of the pharmaceutical composition, and the composition is prepared into multiple conventional dosage forms such as emulsion, ointment preparations and the like and is used for treating easily reoccurring diseases caused by the HPV infection, such as condyloma acuminate, cervical cancer, carcinoma of vulva, carcinoma of penis, anal carcinoma, carcinoma of mouth and the like. The pharmaceutical composition disclosed by the invention has the advantages of short usage course of treatment, small active ingredient amount, exact curative effects, low reoccurrence rate, small side effects, low treatment cost and the like, and brings an excellent therapy pathway to patients.

Description

technical field [0001] The present invention relates to the technical field of polypeptide pharmaceutical preparations, in particular to pharmaceutical compositions containing F1 and F3 polypeptides [0002] and its application in the treatment of HPV infection diseases. Background technique [0003] Chronic human papillomavirus (human papillomavirus, HPV) infection can cause a variety of diseases. Cancers of the cervix, vulva, penis, anus, and mouth can all be caused by infection with HPV. Cervical cancer is one of the common malignant tumors, and its incidence rate is the second among female tumors. Its occurrence is closely related to the persistent infection of HPV, especially HPV types 16 and 18. Although vaccines for the prevention of HPV infection have been used since 2006, such vaccines are only suitable for healthy individuals who have never been infected, and are ineffective against current HPV infection and the diseases it causes. At present, there are still ab...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/46C07K1/20C07K1/06C07K1/04A61K38/17A61P31/20A61P35/00A61P17/12
CPCA61K38/00C07K14/463A61K31/4745A61K38/1703A61K39/12A61P35/00C12N2710/20034A61K2039/585
Inventor 刘晓松倪国颖王天放
Owner ZHONG AO BIOMEDICAL TECH (GUANGDONG) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap